Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells

@article{Sytkowski2007DoesEH,
  title={Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells},
  author={A. Sytkowski},
  journal={Science's STKE},
  year={2007},
  volume={2007},
  pages={pe38 - pe38}
}
Erythropoietin (Epo) stimulates red blood cell production by docking with its cognate receptor on the erythroid progenitor cell and triggering an array of signaling pathways that inhibit apoptosis and promote cell proliferation and differentiation. In its pharmaceutical forms, epoetin and darbepoetin, Epo is widely used to treat various anemias, including those associated with cancer. The Epo receptor is also expressed by nonhematopoietic cells, including cancer cells, and Epo exhibits a… Expand
Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
TLDR
This article presents a short discussion of EPO, receptors involved in EPO signal transduction, and their action on non-hematopoietic cells, followed by a more detailed presentation of both pre-clinical and clinical data that demonstrate EPO’s action on cancer cells, as well as tumor angiogenesis and lymphangiogenesis. Expand
The erythropoietin receptor in normal and cancer tissues.
TLDR
Recommendations are that the administration of erythropoiesis stimulating agents (ESAs) should be administered at the lowest dose sufficient to avoid the need for red blood cell transfusions, and ESAs should not be used in patients with active malignant disease not receiving chemotherapy or radiotherapy. Expand
The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells.
TLDR
Telomere shortening caused by long term inhibition of the enzyme abolished the effect of EPO, suggesting that EPO effects on cancer cells are related to telomere dynamics. Expand
Erythropoietin increases macrophage-mediated T cell suppression.
TLDR
It is suggested that EPO could increase T cell suppression in the TME by acting directly on macrophages by inhibiting iNOS by enzyme inhibition, genetic ablation, or blocking IFNγ signaling. Expand
Erythropoietin Stimulates Tumor Growth via EphB4.
TLDR
EphB4 is identified as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression and provides clinically significant dimension to the biology of erythropoietin. Expand
The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review.
TLDR
The modulation by rhEPO of tumor cell response to anticancer agents is coincident with modulation of multiple signaling pathways, BCL-2 family proteins, caspases and NFkB. Expand
Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
TLDR
A careful gathering of Epo/EpoR biomolecular information enabled us to assemble an unexpected jigsaw puzzle which could explain most of the controversies of preclinical and clinical studies. Expand
Erythropoietin drives breast cancer progression by activation of its receptor EPOR
TLDR
Experiments in vitro and in vivo demonstrate that functional EPOR signaling is essential for the tumor-promoting effects of EPO and underline the importance of the EPO-EPOR axis in breast tumor progression. Expand
Endogenous erythropoietin and erythropoietin receptors in colorectal cancer; can we answer the questions?
TLDR
There are many open questions about role of Epo/EpoR in CRC and the identification of at-risk group remains a clinical challenge, according to the author. Expand
Erythropoietin Receptor Contributes to Melanoma Cell Survival in vivo
TLDR
Recombinant Epo fails to stimulate melanoma growth in vivo, but the treatment increased vascular size in the xenografts and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Induction of Signalling in Non-Erythroid Cells by Pharmacological Levels of Erythropoietin
TLDR
It is demonstrated that EPO, at pharmacological concentrations, can activate three major signalling cascades, viz. the Jak2/STAT5, Ras/ERK and PI3K/Akt pathways in non-small cell lung carcinoma (NSCLC) cell lines. Expand
Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells
TLDR
The hypothesis that Epo activates the Akt signaling pathway in human melanoma cells and thus promotes the survival of tumor cells is examined. Expand
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.
  • M. Brines, G. Grasso, +13 authors A. Cerami
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2004
TLDR
The hypothesis that betacR in combination with the EpoR expressed by nonhematopoietic cells constitutes a tissue-protective receptor is hypothesized and supported, as predicted, neither Epo nor CEpo was active in cardiomyocyte or spinal cord injury models performed in the betac R knockout mouse. Expand
Erythropoietin regulates tumour growth of human malignancies.
TLDR
The findings suggest that Epo is indispensable for the growth and viability of malignant tumour and also that the deprivation of Epo signalling may be a promising therapy for human malignancy. Expand
Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.
TLDR
An endothelial cell protein of 45 kDa is identified as the principal receptor associated with this mitogenic effect of erythropoietin on human umbilical vein endothelial cells and bovine adrenal capillary endothelial Cells. Expand
Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.
TLDR
A role for autocrine or paracrine Epo signaling in the malignant progression and local invasiveness of head and neck cancer is supported and may also be activated by recombinant Epo therapy and could potentially produce detrimental effects in rhEpo-treated cancer patients. Expand
Expression of erythropoietin receptor splice variants in human cancer.
TLDR
Findings indicate the expression of multiple EPOR isoforms in human cancer cells that may modulate the cellular effects of recombinant human EPO or EPO-EPOR antagonists. Expand
A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells.
TLDR
It is shown that Epo prevents staurosporine-induced apoptosis of differentiated human neuroblastoma SH-SY5Y cells, and activates the STAT5, AKT and MAPK signaling pathways. Expand
Expression of Erythropoietin and Erythropoietin Receptor in Cervical Cancer and Relationship to Survival, Hypoxia, and Apoptosis
TLDR
The data suggest a critical role of the endogenous Epo/EpoR system in cervical cancer and their relationship with intratumoral pO2 levels as well as with survival in patients with cervical cancer. Expand
Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells
Erythropoietin (Epo), the principal regulator of erythroid progenitor survival, growth, and differentiation, initiates its action by binding to its cognate cell surface receptor (EpoR). EpoR haveExpand
...
1
2
3
4
5
...